CytoSorbents reports preliminary Q4 product revenue $9.0M-$9.2M, 22-25% YoY growth; full-year ~$35.5M, 14% growth

Cytosorbents Corp

2024-FY EPS reported -$0.38 revenue$35,594,520

Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.
Full-year 2024 product revenue est $35.4M-$35.6M, ~14% growth vs $31.1M in FY 2023.
Q4 gross margin est ~70%, up from 61% in Q3 2024, driven by resolution of manufacturing issues.
Rights offering commenced Dec 23, 2024; subscription period ends Jan 10, 2025.
FDA and Health Canada reviews for DrugSorb-ATR marketing application underway; decisions expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.